Last updated on September 2018

Single and Multiple Dose Study of BIIB067 in Adults With Amyotrophic Lateral Sclerosis (ALS)


Brief description of study

The primary objective of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of BIIB067 in adults with ALS. The secondary objective is to evaluate the effects of BIIB067 on levels of superoxide dismutase 1 (SOD1) protein in the cerebrospinal fluid (CSF).

Clinical Study Identifier: NCT02623699

Contact Investigators or Research Sites near you

Start Over

Biogen

Barrow Neurological Institute
Phoenix, AZ United States

Biogen

University of California San Diego Medical Center
La Jolla, CA United States

Biogen

California Pacific Medical Center
San Francisco, CA United States

Biogen

Compass Research, LLC
Orlando, FL United States

Biogen

The Emory Clinic
Atlanta, GA United States

Biogen

Johns Hopkins Hospital
Baltimore, MD United States

Biogen

Massachusetts General Hospital, MA
Boston, MA United States

Biogen

Washington University School of Medicine
Saint Louis, MO United States

Biogen

Volunteer Research Group, LLC
Knoxville, TN United States

Biogen

UZ Leuven
Leuven, Belgium

Biogen

Sunnybrook Health Sciences Centre
Toronto, ON Canada

Biogen

Montreal Neurological Institute Clinical Research Unit
Montreal, QC Canada

Biogen

Groupe Hospitalier Pitie-Salpetriere
Paris, France

Biogen

Universitaetsklinikum Ulm
Ulm, Germany

Biogen

Universit degli Studi di Torino
Torino, Italy

Biogen

Norrlands universitetssjukhus
Umea, Sweden

Biogen

Sheffield Institute for Translational Neuroscience
Sheffield, United Kingdom